Z

Zevra Therapeutics Inc
NASDAQ:ZVRA

Watchlist Manager
Zevra Therapeutics Inc
NASDAQ:ZVRA
Watchlist
Price: 9.43 USD -0.63% Market Closed
Market Cap: 496.2m USD
Have any thoughts about
Zevra Therapeutics Inc?
Write Note

Intrinsic Value

The intrinsic value of one ZVRA stock under the Base Case scenario is 14.25 USD. Compared to the current market price of 9.43 USD, Zevra Therapeutics Inc is Undervalued by 34%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ZVRA Intrinsic Value
14.25 USD
Undervaluation 34%
Intrinsic Value
Price
Z
Worst Case
Base Case
Best Case

Valuation Backtest
Zevra Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ZVRA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ZVRA?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Zevra Therapeutics Inc

Provide an overview of the primary business activities
of Zevra Therapeutics Inc.

What unique competitive advantages
does Zevra Therapeutics Inc hold over its rivals?

What risks and challenges
does Zevra Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Zevra Therapeutics Inc recently?

Summarize the latest earnings call
of Zevra Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Zevra Therapeutics Inc.

Provide P/S
for Zevra Therapeutics Inc.

Provide P/E
for Zevra Therapeutics Inc.

Provide P/OCF
for Zevra Therapeutics Inc.

Provide P/FCFE
for Zevra Therapeutics Inc.

Provide P/B
for Zevra Therapeutics Inc.

Provide EV/S
for Zevra Therapeutics Inc.

Provide EV/GP
for Zevra Therapeutics Inc.

Provide EV/EBITDA
for Zevra Therapeutics Inc.

Provide EV/EBIT
for Zevra Therapeutics Inc.

Provide EV/OCF
for Zevra Therapeutics Inc.

Provide EV/FCFF
for Zevra Therapeutics Inc.

Provide EV/IC
for Zevra Therapeutics Inc.

Show me price targets
for Zevra Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Zevra Therapeutics Inc?

How accurate were the past Revenue estimates
for Zevra Therapeutics Inc?

What are the Net Income projections
for Zevra Therapeutics Inc?

How accurate were the past Net Income estimates
for Zevra Therapeutics Inc?

What are the EPS projections
for Zevra Therapeutics Inc?

How accurate were the past EPS estimates
for Zevra Therapeutics Inc?

What are the EBIT projections
for Zevra Therapeutics Inc?

How accurate were the past EBIT estimates
for Zevra Therapeutics Inc?

Compare the revenue forecasts
for Zevra Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Zevra Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Zevra Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Zevra Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Zevra Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Zevra Therapeutics Inc with its peers.

Analyze the financial leverage
of Zevra Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Zevra Therapeutics Inc.

Provide ROE
for Zevra Therapeutics Inc.

Provide ROA
for Zevra Therapeutics Inc.

Provide ROIC
for Zevra Therapeutics Inc.

Provide ROCE
for Zevra Therapeutics Inc.

Provide Gross Margin
for Zevra Therapeutics Inc.

Provide Operating Margin
for Zevra Therapeutics Inc.

Provide Net Margin
for Zevra Therapeutics Inc.

Provide FCF Margin
for Zevra Therapeutics Inc.

Show all solvency ratios
for Zevra Therapeutics Inc.

Provide D/E Ratio
for Zevra Therapeutics Inc.

Provide D/A Ratio
for Zevra Therapeutics Inc.

Provide Interest Coverage Ratio
for Zevra Therapeutics Inc.

Provide Altman Z-Score Ratio
for Zevra Therapeutics Inc.

Provide Quick Ratio
for Zevra Therapeutics Inc.

Provide Current Ratio
for Zevra Therapeutics Inc.

Provide Cash Ratio
for Zevra Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Zevra Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Zevra Therapeutics Inc?

What is the current Free Cash Flow
of Zevra Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Zevra Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Zevra Therapeutics Inc

Current Assets 99.4m
Cash & Short-Term Investments 89.4m
Receivables 7.8m
Other Current Assets 2.3m
Non-Current Assets 92.1m
Long-Term Investments 6.1m
PP&E 1.4m
Intangibles 75.3m
Other Non-Current Assets 9.3m
Current Liabilities 34.5m
Accounts Payable 24.5m
Accrued Liabilities 540k
Other Current Liabilities 9.5m
Non-Current Liabilities 87.3m
Long-Term Debt 58.9m
Other Non-Current Liabilities 28.4m
Efficiency

Earnings Waterfall
Zevra Therapeutics Inc

Revenue
24.8m USD
Cost of Revenue
-11.5m USD
Gross Profit
13.3m USD
Operating Expenses
-99.6m USD
Operating Income
-86.3m USD
Other Expenses
1.3m USD
Net Income
-84.9m USD

Free Cash Flow Analysis
Zevra Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ZVRA Profitability Score
Profitability Due Diligence

Zevra Therapeutics Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
ROE is Increasing
Exceptional 1-Year Revenue Growth
Positive Gross Profit
25/100
Profitability
Score

Zevra Therapeutics Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

ZVRA Solvency Score
Solvency Due Diligence

Zevra Therapeutics Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Low D/E
37/100
Solvency
Score

Zevra Therapeutics Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ZVRA Price Targets Summary
Zevra Therapeutics Inc

Wall Street analysts forecast ZVRA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZVRA is 21.42 USD with a low forecast of 17.17 USD and a high forecast of 26.25 USD.

Lowest
Price Target
17.17 USD
82% Upside
Average
Price Target
21.42 USD
127% Upside
Highest
Price Target
26.25 USD
178% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ZVRA?

Click here to dive deeper.

Dividends

Zevra Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ZVRA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ZVRA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

ZVRA News

Other Videos

Profile

Zevra Therapeutics Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

501.9m USD

Dividend Yield

0%

Description

Zevra Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. The company is headquartered in Celebration, Florida and currently employs 36 full-time employees. The company went IPO on 2015-04-16. The firm is engaged in creating therapies for diseases with limited or no treatment options. The firm has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and commercial stage assets. The company employs its LAT platform technology to create a portfolio of approved products. Its product candidates include Arimoclomol, KP1077IH, KP1077N and AZSTARYS. Arimoclomol is an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate, which is being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), the Company's prodrug of d-methylphenidate (d-MPH). AZSTARYS is a prodrug for the treatment of ADHD in patients aged six years or older.

Contact

FLORIDA
Celebration
1180 Celebration Boulevard, Suite 103
+13219393416
zevra.com

IPO

2015-04-16

Employees

36

Officers

President, CEO & Director
Mr. Neil F. McFarlane
Co-Founder & Chief Development Officer
Ms. Christal M. M. Mickle M.A.
CFO, Secretary & Treasurer
Mr. R. LaDuane Clifton CPA
Chief Commercial Officer & Executive VP of Business Development
Mr. Joshua M. Schafer M.B.A.
Chief Scientific Officer
Dr. Sven Guenther Ph.D.
Vice President of Investor Relations & Corporate Communications
Ms. Nichol L. Ochsner
Show More
Chief Legal Officer, Secretary & Compliance Officer
Mr. Rahsaan W. Thompson J.D.
Chief People Officer
Ms. Alison Peters
Senior Vice President of Manufacturing
Dr. Christopher M. Lauderback Ph.D.
Senior Vice President of Clinical Development
Dr. Rene A. Braeckman Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one ZVRA stock?

The intrinsic value of one ZVRA stock under the Base Case scenario is 14.25 USD.

Is ZVRA stock undervalued or overvalued?

Compared to the current market price of 9.43 USD, Zevra Therapeutics Inc is Undervalued by 34%.

Back to Top